The stock is likely to decline on the guidance miss despite a solid quarter, as the Exact Sciences acquisition dilution outweighs near-term growth. Monitor second-quarter EPS guidance of $1.25-$1.31 for signs of recovery.
Price Chart
Executive Summary
Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15, a 6% year-over-year increase, but missed consensus by $0.00. Revenue of $11.16B grew 7.8% YoY. The company lowered full-year 2026 adjusted EPS guidance to $5.38-$5.58 (from $5.55-$5.80) due to $0.20 dilution from the Exact Sciences acquisition. Despite strong growth in Established Pharmaceuticals and Medical Devices, the guidance reduction drives a bearish sentiment.
Key Financial Metrics
Key Facts
- First-quarter 2026 adjusted EPS was $1.15, missing consensus of $1.15 by $0.00 but up 6% YoY
- First-quarter 2026 revenue was $11.16B, beating consensus of $11.00B and growing 7.8% YoY
- Full-year 2026 adjusted EPS guidance was lowered to $5.38-$5.58 from $5.55-$5.80 due to $0.20 dilution from the Exact Sciences acquisition
- The company completed the acquisition of Exact Sciences, establishing a new oncology diagnostics business
- Medical Devices sales grew 13.2% YoY, driven by double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management
Financial Impact
The guidance reduction of $0.20 at the midpoint implies a $0.7B annual EPS impact, offsetting the strong quarterly beat
Risk Factors
- Exact Sciences acquisition may underperform, leading to further dilution
- Integration risks from the Exact Sciences acquisition
- Continued pricing pressures in the Nutrition segment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-025365 |
| Document: abt-20260416.htm | 0001628280-26-025365 |
| Document: 0001628280-26-025365-index-headers.html | 0001628280-26-025365 |
| Document: 0001628280-26-025365-index.html | 0001628280-26-025365 |
| Document: 0001628280-26-025365.txt | 0001628280-26-025365 |
| 8-K Data (Synthetic) | 0001628280-26-025365 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 today | ANALYST-UPGRADE | $98.00 awaiting T+5 | awaiting T+5 | — | $96.69 (−1.34%) |
Sep 14, 2026 18d ago | Court Ruling | $103.09 $102.98 | ▼ −0.11% | ▼ −1.77% | $96.69 (−6.21%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $96.69 (−11.88%) |
Aug 11, 2026 7w ago | Court Ruling | $109.72 $112.68 | ▲ +2.70% | ▲ +3.10% | $96.69 (−11.88%) |
Jul 31, 2026 9w ago | Institutional Cluster | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $96.69 (−8.52%) |
Jul 31, 2026 9w ago | Court Ruling | $105.70 $107.81 | ▲ +2.00% | ▼ −1.51% | $96.69 (−8.52%) |
Jul 24, 2026 10w ago | Court Ruling | $103.06 $105.61 | ▲ +2.47% | ▲ +2.10% | $96.69 (−6.18%) |
Jul 16, 2026 11w ago | 8-K | $98.83 $100.75 | ▲ +1.94% | ▲ +3.61% | $96.69 (−2.17%) |
Jul 14, 2026 11w ago | Court Ruling | $88.96 $101.66 | ▲ +14.28% | ▲ +15.57% | $96.69 (+8.69%) |
Jul 7, 2026 12w ago | Court Ruling | $95.84 $88.96 | ▼ −7.18% | ▼ −7.73% | $96.69 (+0.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access